Landogrozumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | GDF-8 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1391726-30-9 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6338H9790N1694O1988S42 |
| Molar mass | 142.9 kDa |
Landogrozumab (INN) is a humanized monoclonal antibody designed for the treatment of muscle wasting disorders.[1][2]
This drug was developed by Eli Lilly & Co.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.